Extract from RNS Jan 10th12 Jan 2019 17:36
We continue to endeavour to progress strategic discussions with regards to our joint venture, Imutex, and to maximise the strategic options available to both companies as we now await publication of the data from the UNISEC and NIAID FLU-v studies in peer reviewed journals
Publication will trigger the next RNS and further major sp bounce forward imo. Any major pharm will want to point to the publications in their business case to enter into any JV or licence acquisition negotiation - again purely imo. Just a question of time now - nothing else as far as i can see.
ATB